Tag:

Genentech

Latest Headlines

Latest Headlines

FDA taps the brakes on Genentech's cobimetinib review

The FDA has opted to delay its review of cobimetinib in order to give regulators more time to consider additional Phase III data provided by Genentech.

Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer

Behind the headlines here at ASCO, you'll find one of the biggest players in immuno-oncology quietly positioning itself to grab a leading role in the fast-emerging market.

UPDATED: Ex-Genentech dream team garners $217M to launch neurodegenerative player Denali

A group of high-profile ex-Genentech execs has rounded up a monster $217 million A round to launch Denali Therapeutics with plans to tackle neurodegenerative diseases like Alzheimer's disease, Parkinson's disease and ALS.

Tiny drugmakers top list of most profitable, but Shire and Gilead are there, too

Who are the most profitable companies in healthcare? Drug companies, with 7 out of 10 slots on a ranking by profit margin. Who are the most profitable drug companies? You might scratch your heads at all but a couple of names.

Genentech joins WaferGen's single cell analysis early-access program

Genentech has joined an early-access program for WaferGen Bio-systems' single cell sequencing technology. The alliance builds on proof-of-concept studies with the Broad Institute and BGI with a view to validating the use of the technology in industrial drug discovery.

Genentech begins search for bioinformatics chief after Gentleman leaves for 23andMe

The fight for top bioinformatics talent is heating up. With 23andMe poaching Robert Gentleman from Genentech, the Roche-owned Big Biotech now finds itself competing with the likes of Google's Calico in its hunt for a replacement.

Celgene, Genentech back clinical trial enrollment challenge

Celgene and Genentech are funding a clinical trial innovation prize focused on doubling the rate of participation in studies of cancer drugs. The project is challenging the crowd to submit ideas and evidence of their effectiveness in return for the chance to land a piece of the $75,000 prize kitty.

Roche's Genentech investing $125M in Oregon plant

With a bunch of biologic drugs in development, Roche's Genentech sees the need for more production capacity. To meet it, the biotech is expanding a fill/finish facility in Oregon, investing more than $100 million on the project and adding dozens of jobs there.

Genentech project to add 100 jobs

Roche's Genentech subsidiary is embarking on a $125 million project that will take Roche's investment in biologics production to over $1 billion and add 100 more jobs to the 500 Roche initially said its biologics expansion would create.

San Francisco requires drugmakers to fund disposal of unused meds

California's Alameda County has held fast against Big Pharma pushback to its drug take-back ordinance that requires drugmakers to fund a program for accepting and destroying unused meds. Now San Francisco has passed its own ordinance to require the same thing.